Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by ValueCaton Jan 12, 2015 3:37pm

108 Views

Post# 23310799

RE:RE:RE:RE:RE:Cipher Pharmaceuticals acquires assets of Melanovus Oncology

they are talking about $20mm to commercialization, if Breakthrough status is granted.
Not huge $.

We need an injection of the American optimism that's driving biotech indices to new highs. No fretting about ebitda there.

Bullboard Posts

Bombardier delivers Global 6500 aircraft to U.S. Army